Skip to main content

Table 4 Treatment is displayed for each year in the 10-year period from 2004 to 2013 for patients with rheumatoid arthritis monitored with outcome measures in an ordinary outpatient clinic

From: Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway

Treatment 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 P value
(n = 404) (n = 604) (n = 620) (n = 743) (n = 796) (n = 969) (n = 1069) (n = 1103) (n = 1113) (n = 1083) (2010–2013)
No treatmenta 44 (10.9) 102 (16.9) 94 (15.2) 110 (14.8) 99 (12.4) 139 (14.3) 122 (11.4) 121 (11.0) 132 (11.9) 106 (9.8) 0.45
Biologic DMARDs (%) 141 (34.9) 170 (28.1) 161 (26.0) 203 (27.3) 234 (29.4) 265 (27.3) 335 (31.3) 342 (31.0) 366 (32.9) 373 (34.4) 0.30
TNF inhibitor 139 (34.4) 170 (28.1) 159 (25.6) 176 (23.7) 192 (24.1) 198 (20.4) 236 (22.1) 221 (20.0) 230 (20.7) 227 (21.0) 0.70
Non-TNF inhibitors 2 (0.5) 0 (0) 2 (0.3) 27 (3.6) 42 (5.3) 67 (6.9) 99 (9.3) 121 (11.0) 136 (12.2) 146 (13.5) 0.016
Synthetic DMARDs (%) 267 (66.1) 349 (58.8) 351 (56.6) 440 (59.2) 471 (59.2) 562 (58.0) 627 (58.7) 667 (60.5) 668 (60.0) 660 (60.9) 0.73
 One synthetic DMARD (%) 243 (60.1) 321 (53.1) 342 (55.2) 423 (56.9) 455 (57.2) 547 (56.4) 612 (57.2) 648 (58.7) 649 (58.3) 649 (59.9) 0.88
 Two synthetic DMARDs (%) 24 (5.9) 28 (4.6) 9 (1.5) 16 (2.2) 16 (2.0) 14 (1.4) 14 (1.3) 18 (1.6) 17 (1.5) 10 (0.9)  
 Three synthetic DMARDs (%) 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0) 1 (0.1) 1 (0.1) 1 (0.1) 2 (0.2) 1 (0.1)  
Biologic and synthetic DMARDs 100 (24.8) 123 (20.4) 114 (18.4) 142 (19.1) 155 (19.5) 176 (18.2) 216 (20.2) 226 (20.5) 234 (21.0) 233 (21.5) 0.58
TNF inhibitor and synthetic DMARDs 99 (24.5) 123 (20.4) 113 (18.2) 129 (17.4) 132 (16.6) 145 (15.0) 167 (15.6) 170 (15.4) 170 (15.3) 162 (15.0) 0.94
Prednisolone (%) 224 (55.4) 334 (55.3) 369 (59.5) 433 (58.3) 486 (61.1) 589 (60.8) 653 (61.1) 653 (59.2) 617 (55.4) 590 (54.5) 0.005
Prednisolone and synthetic DMARDs (%) 152 (37.6) 208 (34.4) 216 (34.8) 270 (36.3) 297 (37.3) 354 (36.5) 377 (35.3) 394 (35.7) 368 (33.1) 346 (31.9) 0.43
Biologic DMARD and prednisolone 53 (13.1) 61 (10.1) 57 (9.2) 78 (10.5) 90 (11.3) 101 (10.4) 125 (11.7) 125 (11.3) 124 (11.1) 120 (11.1) 0.80
Biologic DMARDs            
 Adalimumab (%) 27 (6.7) 50 (8.3) 51 (8.2) 56 (7.5) 58 (7.3) 80 (8.3) 78 (7.3) 70 (6.3) 61 (5.5) 52 (4.8) 0.08
 Certolizumab (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 8 (0.7) 10 (0.9) 21 (1.9) 44 (4.1) 0.000
 Etanercept (%) 60 (14.9) 77 (12.7) 68 (11.0) 73 (9.8) 96 (12.1) 88 (9.1) 98 (9.2) 109 (9.9) 118 (10.6) 104 (9.6) 0.72
 Golimumab (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 26 (2.4) 14 (1.3) 12 (1.1) 9 (0.8) 0.008
 Infliximab (%) 52 (12.9) 43 (7.1) 40 (6.5) 47 (6.3) 38 (4.8) 30 (3.1) 26 (2.4) 18 (1.6) 18 (1.6) 18 (1.7) 0.42
 Abatacept (%) 0 (0) 0 (0) 0 (0) 3 (0.4) 3 (0.4) 5 (0.5) 11 (1.0) 21 (1.9) 23 (2.1) 15 (1.4) 0.19
 Anakinra (%) 2 (0.5) 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Rituximab (%) 0 (0) 0 (0) 1 (0.2) 24 (3.2) 39 (4.9) 58 (6.0) 76 (7.1) 88 (8.0) 102 (9.2) 118 (10.9) 0.013
 Tocilizumab (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0.4) 12 (1.1) 12 (1.1) 11 (1.0) 13 (1.2) 0.97
Synthetic DMARDs            
 Leflunomide (%) 15 (3.7) 31 (5.1) 29 (4.7) 40 (5.4) 44 (5.5) 55 (5.7) 63 (5.9) 64 (5.8) 62 (5.6) 58 (5.4) 0.95
 Methotrexate (%) 212 (52.5) 269 (44.5) 275 (44.4) 349 (47.0) 360 (45.2) 438 (45.2) 496 (46.4) 544 (49.3) 558 (50.1) 551 (50.9) 0.17
 Methotrexate dose weekly (mg) 10.0 (2.3) 10.2 (2.7) 10.6 (2.6) 10.8 (2.8) 11.3 (3.0) 11.9 (3.0) 12.3 (3.4) 12.6 (3.4) 13.2 (3.6) 13.5 (3.8) <0.001
 Sulfasalazine (%) 12 (3.0) 20 (3.3) 21 (3.4) 27 (3.6) 31 (3.9) 31 (3.2) 39 (3.6) 36 (3.3) 32 (2.9) 39 (3.6) 0.73
 Hydroxychloroquine (%) 37 (9.2) 42 (7.0) 24 (3.9) 30 (4.0) 35 (4.4) 39 (4.0) 36 (3.4) 35 (3.2) 31 (2.8) 20 (1.8) 0.14
 Other synthetic DMARDsb (%) 15 (3.7) 15 (2.5) 11 (1.8) 11 (1.5) 16 (2.0) 14 (1.4) 9 (0.8) 7 (0.6) 5 (0.4) 3 (0.3) 0.32
  1. Abbreviations: DMARDs disease-modifying antirheumatic drugs, TNF tumor necrosis factor
  2. Data are presented as numbers and percentages (%) or as mean with standard deviation
  3. χ2 test or linear regression used to test for differences during follow-up for the period from 2010 to 2013
  4. aNo prednisolone, biologic or synthetic DMARDs
  5. bAuranofin, azathioprine, ciclosporin and gold